Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700749 | 1.00 | CRHBP (0.53) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL7997158 | 0.88 | CRHBP (0.54) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL9509221 | 0.88 | CRHBP (0.54) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL6715106 | 0.87 | CRHBP (0.48) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL6715102 | 0.87 | CRHBP (0.48) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL4301791 | 0.86 | CRHBP (0.56) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL21728986 | 0.86 | CRHBP (0.53) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL8742128 | 0.86 | CRHBP (0.56) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL6715110 | 0.86 | CRHBP (0.47) | CRHBPCRHR2MAPTTDP1GAA | |
| SCHEMBL6129749 | 0.84 | CRHBP (0.57) | CRHBPCRHR2MAPTTDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61003066-A | — | — | None | — | — | JP | disclosed |
| WO-2018200498-A1 | COMPOSITIONS AND METHODS FOR ANALYZING CYSTEINE | GEORGETOWN UNIVERSITY (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103025165-B | From the controlled release of macromolecular conjugates | 普罗林科斯有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-0115171-B1 | CONJUGATE HAVING CYTOTOXICITY AND PROCESS FOR THE PREPARATION THEREOF | TEIJIN LIMITED (JP) | 1990-04-18 | — | — | EP | disclosed |
| JP-S613066-A | ASSAY OF THIOL GROUP REACTING GROUP | TEIJIN LTD | 1986-01-09 | — | — | JP | disclosed |
| US-4507234-A | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| EP-0115171-A2 | Conjugate having cytotoxicity and process for the preparation thereof | TEIJIN LIMITED (JP) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | CRHBP 355/4885CRHR2 312/4885MAPT 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.